{"title":"肥胖患者心血管风险的新生物标志物","authors":"A. Berezin","doi":"10.17554/J.ISSN.2309-6861.2017.04.129","DOIUrl":null,"url":null,"abstract":"Obesity remains a leading cause of cardiovascular (CV) events and diabetes worldwide. Although there are at least two main body-size phenotypes (metabolically healthy and metabolically non-healthy) of individuals with established obesity, the cardiometabolic risk amongst these patients’ populations extremely distinguishes. The editorial is discussed the controversies regarding obese paradox and the probabilities to stratify the patients with established obesity in cardiometabolic risk. It is suggested that the biomarkers could predict CV events in patients depending on obese phenotypes. The role of metabolic biomarkers, progenitor cells, natriuretic peptides, inflammatory cytokines and galectin-3 are discussed.","PeriodicalId":92802,"journal":{"name":"Journal of clinical cardiology and cardiovascular therapy","volume":"10 1","pages":"676-680"},"PeriodicalIF":0.0000,"publicationDate":"2017-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":"{\"title\":\"Novel Biomarkers for Cardiovascular Risk in Obese Patients\",\"authors\":\"A. Berezin\",\"doi\":\"10.17554/J.ISSN.2309-6861.2017.04.129\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Obesity remains a leading cause of cardiovascular (CV) events and diabetes worldwide. Although there are at least two main body-size phenotypes (metabolically healthy and metabolically non-healthy) of individuals with established obesity, the cardiometabolic risk amongst these patients’ populations extremely distinguishes. The editorial is discussed the controversies regarding obese paradox and the probabilities to stratify the patients with established obesity in cardiometabolic risk. It is suggested that the biomarkers could predict CV events in patients depending on obese phenotypes. The role of metabolic biomarkers, progenitor cells, natriuretic peptides, inflammatory cytokines and galectin-3 are discussed.\",\"PeriodicalId\":92802,\"journal\":{\"name\":\"Journal of clinical cardiology and cardiovascular therapy\",\"volume\":\"10 1\",\"pages\":\"676-680\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2017-06-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of clinical cardiology and cardiovascular therapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.17554/J.ISSN.2309-6861.2017.04.129\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of clinical cardiology and cardiovascular therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17554/J.ISSN.2309-6861.2017.04.129","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Novel Biomarkers for Cardiovascular Risk in Obese Patients
Obesity remains a leading cause of cardiovascular (CV) events and diabetes worldwide. Although there are at least two main body-size phenotypes (metabolically healthy and metabolically non-healthy) of individuals with established obesity, the cardiometabolic risk amongst these patients’ populations extremely distinguishes. The editorial is discussed the controversies regarding obese paradox and the probabilities to stratify the patients with established obesity in cardiometabolic risk. It is suggested that the biomarkers could predict CV events in patients depending on obese phenotypes. The role of metabolic biomarkers, progenitor cells, natriuretic peptides, inflammatory cytokines and galectin-3 are discussed.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
